 |
Glob Reg Health Technol Assess 2022; 9: 30 ISSN 2283-5733 | DOI: 10.33393/grhta.2022.2383 ERRATUM |
 |
Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
Received: February 9, 2022
Accepted: February 11, 2022
Published online: February 17, 2022
Global & Regional Health Technology Assessment - ISSN 2283-5733 - www.aboutscience.eu/grhta
© 2022 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
Commercial use is not permitted and is subject to Publisher’s permissions. Full information is available at www.aboutscience.eu
In the article “Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy”, (1) which appeared in Volume 8, Issue 1 of Global & Regional Health Technology Assessment, the values appearing in Fig. 5 C and D, inadvertently repeated the values reported in Fig. 5 A and B. Affected data have been corrected in the article now appearing online. The authors apologize for any inconvenience caused to the readers by these changes, which do not affect the final results of the study.
The final version of this article is available online and includes a reference to this correction.